预约演示

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

2024-01-23

免疫疗法临床2期并购

Calluna will use the funding to develop four immunotherapy candidates.

Calluna Maria Dryfhout via Shutterstock.

European biotechs Oxitope Pharma and Arxx Therapeutics have merged to form Calluna Pharma, raising €75m ($81m) in a Series A funding round.

Free ReportHow is Oxitope PharmaeuticArxx Therapeuticsing?Calluna Pharma

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.

GlobalData’s expansive report examines the business environment and trends that shape the BioCOVID-19 pandemicdustry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Access the report to:

Benchmark the impact of major themes on the Biopharmaceutical industry.

Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.

Evaluate the effects of COVID-19 on the sector.

Download the full reportCOVID-19rstand what to expect and how to align your strategies for success.

Submit

Country Code *

UK (+44)

USA (+1)

Algeria (+213)

Andorra (+376)

Angola (+244)

Anguilla (+1264)

Antigua & Barbuda (+1268)

Argentina (+54)

Armenia (+374)

Aruba (+297)

Australia (+61)

Austria (+43)

Azerbaijan (+994)

Bahamas (+1242)

Bahrain (+973)

Bangladesh (+880)

Barbados (+1246)

Belarus (+375)

Belgium (+32)

Belize (+501)

Benin (+229)

Bermuda (+1441)

Bhutan (+975)

Bolivia (+591)

Bosnia Herzegovina (+387)

Botswana (+267)

Brazil (+55)

Brunei (+673)

Bulgaria (+359)

Burkina Faso (+226)

Burundi (+257)

Cambodia (+855)

Cameroon (+237)

Canada (+1)

Cape Verde Islands (+238)

Cayman Islands (+1345)

Central African Republic (+236)

Chile (+56)

China (+86)

Colombia (+57)

Comoros (+269)

Congo (+242)

Cook Islands (+682)

Costa Rica (+506)

Croatia (+385)

Cuba (+53)

Cyprus North (+90392)

Cyprus South (+357)

Czech Republic (+42)

Denmark (+45)

Djibouti (+253)

Dominica (+1809)

Dominican Republic (+1809)

Ecuador (+593)

Egypt (+20)

El Salvador (+503)

Equatorial Guinea (+240)

Eritrea (+291)

Estonia (+372)

Ethiopia (+251)

Falkland Islands (+500)

Faroe Islands (+298)

Fiji (+679)

Finland (+358)

France (+33)

French Guiana (+594)

French Polynesia (+689)

Gabon (+241)

Gambia (+220)

Georgia (+7880)

Germany (+49)

Ghana (+233)

Gibraltar (+350)

Greece (+30)

Greenland (+299)

Grenada (+1473)

Guadeloupe (+590)

Guam (+671)

Guatemala (+502)

Guinea (+224)

Guinea - Bissau (+245)

Guyana (+592)

Haiti (+509)

Honduras (+504)

Hong Kong (+852)

Hungary (+36)

Iceland (+354)

India (+91)

Indonesia (+62)

Iran (+98)

Iraq (+964)

Ireland (+353)

Israel (+972)

Italy (+39)

Jamaica (+1876)

Japan (+81)

Jordan (+962)

Kazakhstan (+7)

Kenya (+254)

Kiribati (+686)

Korea North (+850)

Korea South (+82)

Kuwait (+965)

Kyrgyzstan (+996)

Laos (+856)

Latvia (+371)

Lebanon (+961)

Lesotho (+266)

Liberia (+231)

Libya (+218)

Liechtenstein (+417)

Lithuania (+370)

Luxembourg (+352)

Macao (+853)

Macedonia (+389)

Madagascar (+261)

Malawi (+265)

Malaysia (+60)

Maldives (+960)

Mali (+223)

Malta (+356)

Marshall Islands (+692)

Martinique (+596)

Mauritania (+222)

Mayotte (+269)

Mexico (+52)

Micronesia (+691)

Moldova (+373)

Monaco (+377)

Mongolia (+976)

Montserrat (+1664)

Morocco (+212)

Mozambique (+258)

Myanmar (+95)

Namibia (+264)

Nauru (+674)

Nepal (+977)

Netherlands (+31)

New Caledonia (+687)

New Zealand (+64)

Nicaragua (+505)

Niger (+227)

Nigeria (+234)

Niue (+683)

Norfolk Islands (+672)

Northern Marianas (+670)

Norway (+47)

Oman (+968)

Palau (+680)

Panama (+507)

Papua New Guinea (+675)

Paraguay (+595)

Peru (+51)

Philippines (+63)

Poland (+48)

Portugal (+351)

Puerto Rico (+1787)

Qatar (+974)

Reunion (+262)

Romania (+40)

Russia (+7)

Rwanda (+250)

San Marino (+378)

Sao Tome & Principe (+239)

Saudi Arabia (+966)

Senegal (+221)

Serbia (+381)

Seychelles (+248)

Sierra Leone (+232)

Singapore (+65)

Slovak Republic (+421)

Slovenia (+386)

Solomon Islands (+677)

Somalia (+252)

South Africa (+27)

Spain (+34)

Sri Lanka (+94)

St. Helena (+290)

St. Kitts (+1869)

St. Lucia (+1758)

Sudan (+249)

Suriname (+597)

Swaziland (+268)

Sweden (+46)

Switzerland (+41)

Syria (+963)

Taiwan (+886)

Tajikstan (+7)

Thailand (+66)

Togo (+228)

Tonga (+676)

Trinidad & Tobago (+1868)

Tunisia (+216)

Turkey (+90)

Turkmenistan (+7)

Turkmenistan (+993)

Turks & Caicos Islands (+1649)

Tuvalu (+688)

Uganda (+256)

UK (+44) -->

Ukraine (+380)

United Arab Emirates (+971)

Uruguay (+598)

USA (+1) -->

Uzbekistan (+7)

Vanuatu (+678)

Vatican City (+379)

Venezuela (+58)

Vietnam (+84)

Virgin Islands - British (+1284)

Virgin Islands - US (+1340)

Wallis & Futuna (+681)

Yemen (North)(+969)

Yemen (South)(+967)

Zambia (+260)

Zimbabwe (+263)

Country *

USA

Afghanistan

Åland Islands

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antarctica

Antigua and Barbuda

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bermuda

Bhutan

Bolivia

Bonaire, Sint Eustatius and Saba

Bosnia and Herzegovina

Botswana

Bouvet Island

Brazil

British Indian Ocean Territory

Brunei Darussalam

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Cape Verde

Cayman Islands

Central African Republic

Chad

Chile

China

Christmas Island

Cocos Islands

Colombia

Comoros

Congo

Democratic Republic of

the Congo

Cook Islands

Costa Rica

Côte d"Ivoire

Croatia

Cuba

Curaçao

Cyprus

Czech Republic

Denmark

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Falkland Islands

Faroe Islands

Fiji

Finland

France

French Guiana

French Polynesia

French Southern Territories

Gabon

Gambia

Georgia

Germany

Ghana

Gibraltar

Greece

Greenland

Grenada

Guadeloupe

Guam

Guatemala

Guernsey

Guinea

Guinea-Bissau

Guyana

Haiti

Heard Island and McDonald Islands

Holy See

Honduras

Hong Kong

Hungary

Iceland

India

Indonesia

Iran

Iraq

Ireland

Isle of Man

Israel

Italy

Jamaica

Japan

Jersey

Jordan

Kazakhstan

Kenya

Kiribati

North Korea

South Korea

Kuwait

Kyrgyzstan

Lao

Latvia

Lebanon

Lesotho

Liberia

Libyan Arab Jamahiriya

Liechtenstein

Lithuania

Luxembourg

Macao

Macedonia, The Former

Macaolav Republic of

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Martinique

Mauritania

Mauritius

Mayotte

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Netherlands

New Caledonia

New Zealand

Nicaragua

Niger

Nigeria

Niue

Norfolk Island

Northern Mariana Islands

Norway

Oman

Pakistan

Palau

Palestinian Territory

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Pitcairn

Poland

Portugal

Puerto Rico

Qatar

Réunion

Romania

Russian Federation

Rwanda

Saint Helena, Ascension and Tristan da Cunha

Saint Kitts and Nevis

Saint Lucia

Saint Pierre and Miquelon

Saint Vincent and The Grenadines

Samoa

San Marino

Sao Tome and Principe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Singapore

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Georgia and The South

Sandwich Islands

Spain

Sri Lanka

Sudan

Suriname

Svalbard and Jan Mayen

Swaziland

Sweden

Switzerland

Syrian Arab Republic

Taiwan

Tajikistan

Tanzania

Thailand

Timor-Leste

Togo

Tokelau

Tonga

Trinidad and Tobago

Tunisia

Turkey

Turkmenistan

Turks and Caicos Islands

Tuvalu

Uganda

Ukraine

United Arab Emirates

US Minor Outlying Islands

Uruguay

Uzbekistan

Vanuatu

Venezuela

Vietnam

British Virgin Islands

US Virgin Islands

Wallis and Futuna

Western Sahara

Yemen

Zambia

Zimbabwe

Kosovo

-->

-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you.You will recieve your mail in sometime.So, please check your email to download the Report.

Go deeper with GlobalData

ReportsLOA and PTSR Model - Monoclonal Antibody Conjugate 3 To Target Egfr For Oncology in Malignant Mes...

ReportsLOA and PTSR Model - Monoclonal Antibody Conjugate 3 To Target Egfr For Oncology in Non-Small Cel...

Premium Insights

The gold standard of business intelligence.Egfr

Find out more

Related Company ProfilesBoehringer Ingelheim International GmbHGSK plcEgfr all

Led by existing lead investors Forbion, Sarsia, p53, and Investinor, the funding from the round will go towards a pipeline of monoclonal antibodies targeting immunological diseases.

Calluna’s lead candidate CAL101 is a monoclonal antibody (mAb) designed to neutralise S100A4, a damage-associated molecular pattern (DAMP) protein. When released in excess or at the wrong time, DAMPs can contribute to the development and progression of diseases involving inflammation and tissue damage such as rheumatoid arthritis, steroid-insensitive asthma, chronic kidney disease, and idiopathic pulmonary fibrosis.

CAL102, a monoclonal antibody that neutralises oxidised phospholipids, is another therapy in development by Calluna. It acts by disrupting the underlying pathways associated with conditions characterised by inflammation and fibrosis.

The company has two other candidates, CAL103 and CAL104, which are both in the discovery phase.

Netherlands-based Oxitope launched in 20Sarsiafep53ears after Norway-based Arxx in 2018, with both startups focusing energy on therapeutic antibodies.immunological diseases

It’s already been a big yCAL101r immunotherapies. Earlier this month, pharma giant BoeS100A4r Ingelheim teamed up with 3T Biosciences in a deal totalling $538.5m to advance cancer immunotherapies, using 3T’s T-Cell Receptor Antigen and Cross-Reactivity Engine (TRACE) discinflammationrm to discover and develop rheumatoid arthritis steroid-insensitive asthma chronic kidney disease idiopathic pulmonary fibrosis

CAL102evelopment comes after GSK purchased Aiolos Bio in a large $1.4bn acquisition, granting GSK access to Aiolos’ monoclonal antibody AIO-001. The candidate, soon to be investigated in a Phase II study, tainflammationkine fibrosisto play a role in asthma and other inflammation diseases.

In the announcement accompanying the fCAL103 rounCAL104luna chief executive officer John Montana said: “In joining forces, these two key players in the innate immunology space have created an exciting new clinical company that has four promising therapies in its pipeline with excellent preclinical proof-of-concept data.”

Free ReportHow is Oxitopepharmaceutical industry evolving?Arxx

2021 was a year of continued innovation and change in the Biopharmaceutical industrBoehringer Ingelheimandemic continue3T Biosciencestoll on businesses worldwide, it’s time cancerk for new ways to create valuT-Cell Receptorthe future, and remain competitive in the ever-changing landscape.

GlobalData’s expansive reportGSKamines the Aiolos Bionvironment and trends that shape the BiopGSKmaceutical Aiolosry. We highlight the mAIO-001actful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influenceasthmah prospectsinflammation diseases